← Back to Search

11C-HY-2-15 Radiotracer for Tauopathies

Q: Are individuals aged 25 and older able to partake in this testing?

Participants in this study should fall within the age range of 40 to 80 years old.

Q: Is enrollment for this research project currently open?

The listing for this clinical trial on clinicaltrials.gov confirms that it is not recruiting participants at this time, despite having been initially posted on July 20th of the current year and last updated September 6th. Fortunately, there are 10 other trials actively seeking patients currently.

Q: Might I be eligible to participate in this research endeavor?

Qualifying for this medical study requires tauopathies in individuals aged 40 to 80 years old. At the moment, approximately 70 prospects are being considered for enrollment.

Phase < 1

Recruiting

Research Sponsored by University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants must be male or female adults from 40 to 80 years of age

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 weeks

Awards & highlights

Study Summary

This trial will study a new radiotracer to detect abnormal brain deposits of a protein in people with Multiple System Atrophy (MSA), Parkinson's and Progressive Supranuclear Palsy. Funded by NIH, 5 universities are collaborating.

Who is the study for?

Adults aged 40-80 with Multiple System Atrophy (MSA), Parkinson's disease (PD), progressive supranuclear palsy (PSP), or healthy volunteers can join. Participants must understand the study and consent, or have a partner to assist. Brain donation is optional for PD/MSA/PSP subjects.Check my eligibility

What is being tested?

The trial tests a new brain imaging agent called 11C-HY-2-15 in MSA patients compared to those with PD, PSP, and healthy individuals. It involves neurological assessments, PET scans for amyloid and alpha-synuclein proteins, and MRI of the brain.See study design

What are the potential side effects?

Potential side effects may include discomfort from imaging procedures like PET scans or MRIs, reactions to tracer injections such as mild pain or bruising at injection sites, and possible allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 40 and 80 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Organ biodistribution

PET uptake of tracer

Secondary outcome measures

Adverse events

Trial Design

1Treatment groups

Experimental Treatment

Group I: 11C-HY-2-15 PETExperimental Treatment4 Interventions

Participants will undergo 11C-HY-2-15 PET scan, they may also have a brain MRI and Amyloid PET scan as well as neurological assessments

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

brain MRI

2010

Completed Phase 2

~70

Neurological assessments

2021

N/A

~120

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor

2,005 Previous Clinical Trials

42,882,213 Total Patients Enrolled

2 Trials studying Tauopathies

124 Patients Enrolled for Tauopathies

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals aged 25 and older able to partake in this testing?

"Participants in this study should fall within the age range of 40 to 80 years old."

Answered by AI

Is enrollment for this research project currently open?

"The listing for this clinical trial on clinicaltrials.gov confirms that it is not recruiting participants at this time, despite having been initially posted on July 20th of the current year and last updated September 6th. Fortunately, there are 10 other trials actively seeking patients currently."

Answered by AI

Might I be eligible to participate in this research endeavor?

"Qualifying for this medical study requires tauopathies in individuals aged 40 to 80 years old. At the moment, approximately 70 prospects are being considered for enrollment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15

2023. "Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06032026.